Long-acting beta2-agonist (LABA) in combination with a long-acting muscarinic agonist (LAMA) as effective as LABA plus inhaled corticosteroid (ICS), as measured by COPD exacerbation rates.

There were 137,833 in the cohort: 30,829 started LAMA-LABA therapy and 107,004 started ICS-LABA therapy. Half of the patients were women (50.4%), and the mean age was 70.2 years.

In the FLAME trial, we investigated whether the LABA indacaterol (110 μg) plus the LAMA glycopyrronium (50 μg) once daily would be at least as effective as the LABA salmeterol (50 μg) plus the ...

The new long-acting muscarinic antagonist and long-acting beta-agonist (LAMA/LABA) fixed dose combination (FDC) inhaler may be a better option than inhaled corticosteroids (ICS) for long-term use.

Lung function was significantly improved with LAMA/LABA therapy compared with patients receiving preoperative LAMA therapy (FEV1, 223.1 mL vs. 130 mL; FEV 1 percent predicted, 10.8% vs. 6.8%).

Among patients with COPD who complain of dyspnea or exercise intolerance, we recommend LABA/LAMA combination therapy over LABA or LAMA monotherapy (strong recommendation, moderate certainty evidence).

Overall results demonstrated that for the LABA/LAMA cohort cardiovascular event frequency was 2.11% compared to 3.41% in the LABA/ICS cohort. Cerebrovascular event frequency was 0.42% for LABA ...

In a cohort study, Feldman and colleagues analyzed 137,833 adults (mean age, 70.2 years; 50.4% women) from Optum’s Clinformatics Data Mart with COPD who were newly prescribed either LAMA-LABA ...

What about LAMA add-on to ICS/LABA not improving symptoms or quality of life? Results from meta-analyses published in 2015 and 2018 that evaluated LAMA add-on were conflicting. One found an effect ...

This group (excluding those with no follow-up visits) comprised 340 patients who switched from triple therapy to a fixed-dose LABA/LAMA product and 784 who remained on triple therapy.

The addition of a long-acting muscarinic antagonist (LAMA) to a long-acting beta agonist (LABA) is better for COPD patients than the addition of an inhaled corticosteroid, data from two studies show.

Overall results demonstrated that for the LABA/LAMA cohort cardiovascular event frequency was 2.11% compared to 3.41% in the LABA/ICS cohort.